Posts by Yin, Jiale

Editor’s Note: Since the PACIFIC study established sequential immunotherapy following chemoradiotherapy as the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), the global focus has shifted…

At the recent 7th Tianfu Oncology Conference, Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences, delivered a keynote presentation titled “Integrative Strategies in Lung Cancer: Targeted Therapy, Immunotherapy, and ADC Management.”

A new study led by Dr. Rafael Nambo Venegas and colleagues, published in Metabolomics (Feb 2025), presents a high-accuracy predictive model for forecasting response to neoadjuvant therapy in breast cancer…

The 2025 CSCO Guidelines Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was successfully held in Jinan, April 18–19, 2025. Leading experts from across the country gathered once again to exchange cutting-edge research, discuss clinical hot topics, and witness the release of updated CSCO guidelines. Oncology Frontier had the honor of interviewing the conference chair, CSCO Council President, and Academician Jinming Yu of Shandong Cancer Hospital, who shared insights into proton therapy, combined radiotherapy and immunotherapy, and CSCO’s path toward deeper international collaboration.

On April 12, 2025, the “Best of St. Gallen 2025” session, co-hosted by the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC) and the St. Gallen International Breast Cancer Conference (SGBCC), was successfully held during the National Breast Cancer Conference in China.

At the European Lung Cancer Congress (ELCC), the prestigious Heine H. Hansen Award was presented to Professor Keith Kerr, a pathologist from the Aberdeen Royal Infirmary, in recognition of his outstanding contributions to oncology research. The announcement was made by ELCC co-chairs Professor Enrico Ruffini, a thoracic surgeon from the Università di Torino, and Professor Myung-Ju Ahn, a medical oncologist from Samsung Medical Center - Sungkyunkwan University School of Medicine, Seoul/KR

The 2025 National Breast Cancer Conference, held in Beijing from April 11 to 13, featured the highly anticipated update to the CSCO Guidelines for the Diagnosis and Treatment of Breast Cancer (CSCO BC Guidelines). The latest edition further refines stratified treatment strategies and emphasizes the importance of both precision medicine and combination therapies—providing more detailed and practical guidance for clinicians. To explore the key updates, Oncology Frontier invited Prof. Chunfang Hao from the Tianjin Cancer  Hospital (Airport Hospital) to elaborate on recent advances in the endocrine management of hormone receptor-positive (HR+) metastatic breast cancer (mBC).

A phase II clinical study on the sequential use of Adebrelimab combined with chemotherapy followed by thoracic radiotherapy has garnered widespread attention at ASCO 2024, particularly for its impact on the treatment of extensive-stage small cell lung cancer (ES-SCLC).The results are striking: the regimen significantly prolonged progression-free survival (PFS) and overall survival (OS) compared to existing standards, while maintaining a favorable safety profile. Most notably, this strategy set a new survival benchmark for first-line immunotherapy in SCLC, demonstrating the value of integrating immune checkpoint inhibition with thoracic radiotherapy. This innovative approach represents a major step forward in SCLC treatment and offers renewed hope for patients battling this aggressive disease. In light of these findings, Oncology Frontier invited Academician Jinming Yu to share insights into the study design, key outcomes, and its clinical implications. The following is a summary of his expert commentary.